India's First Indigenous Drug
Eluting Stent Receives CE Approval
Sahajanand Medical Technologies (SMT)
has received CE approval (Conformité Européenne), an authorisation certificate,
for qualification for the sale of Infinnium in European community and many other
countries in the world. The Infinnium paclitaxel eluting coronary stent system
is the first (Asian) indigenously developed coronary stent for the treatment of
coronary artery disease (CAD) and offers unmatched clinical outcomes with
excellent safety profile.
The CE approval of Infinnium was
based on stringent review of chemical pharmaceutical data, pre-clinical data and
clinical (human trials) data demonstrating sustained long term efficacy and
excellent safety, informs a company release.
"SMT is proud to be the only
Indian company to have received CE mark for our indigenously developed Infinnium
paclitaxel eluting coronary stent which will help make the DES therapy
affordable for millions of patients suffering from CAD.
Besides SMT, there are only 4
more companies in the world to have got the CE authorisation for their DES out
of 40 companies worldwide.
(Ref : Chronicle Pharmabiz
dated December 15, 2005)
Hindustan Latex Sets Rs. 1000
Cr. Turnover Target By 2010
Hindustan Latex Limited (HLL) has
drawn up an ambitious turnover target of Rs 1000 crore by 2010 and to achive
this it has chalked out a comprehensive plan of expanding its portfolio of
health care and contraceptive products. The company has signed a Memorandum of
Understanding with AIMU Medical Science and Technology Ltd, Anshan, China, for
introducing a new generation of intra uterine devices (IUD).
"The IUDs are memory MCU IUDs.
The uniqueness of these IUDs is that they regain their original shape, even if
distorted, at body temperature. The memory IUD has an effective life of over 8
years," said the company sources. HLL has commenced the marketing of its spiral
condoms by the brand name MOODS. The product was launched at Hyderabad recently.
Further, the company has launched
women's healthcare pharma division to cater to the reproductive healthcare needs
of women. The division will initially focus on the gynaecology segment, the
products of which will be promoted by the doctors. All products for this
division will be manufactured at HLL's Kanagala Plant. The division will cover
all sectors of women health issues like autoimmune diseases, hormone-gynaecological
infections, sexually transmitted diseases, hormone related disorders,
osteoporosis, cancer and urinary bladder disorders.
Another major project on the
anvil is the production of anti retro viral (ARV) drug. The commercial
production will be undertaken by Kanagala plant for which the formulation
development is under process. Trial license from the state drugs control
authority has been obtained.
(Ref : Chronicle Pharmabiz
dated December 22, 2005)